Search

Your search keyword '"Jeremiah, Sundararaj Stanleyraj"' showing total 32 results
Start Over Author "Jeremiah, Sundararaj Stanleyraj"
32 results on '"Jeremiah, Sundararaj Stanleyraj"'

2. Highly specific monoclonal antibodies and epitope identification against SARS-CoV-2 nucleocapsid protein for antigen detection tests

Author

Yamaoka, Yutaro, Miyakawa, Kei, Jeremiah, Sundararaj Stanleyraj, Funabashi, Rikako, Okudela, Koji, Kikuchi, Sayaka, Katada, Junichi, Wada, Atsuhiko, Takei, Toshiki, Nishi, Mayuko, Shimizu, Kohei, Ozawa, Hiroki, Usuku, Shuzo, Kawakami, Chiharu, Tanaka, Nobuko, Morita, Takeshi, Hayashi, Hiroyuki, Mitsui, Hideaki, Suzuki, Keita, Aizawa, Daisuke, Yoshimura, Yukihiro, Miyazaki, Tomoyuki, Yamazaki, Etsuko, Suzuki, Tadaki, Kimura, Hirokazu, Shimizu, Hideaki, Okabe, Nobuhiko, Hasegawa, Hideki, and Ryo, Akihide

Published
2021
Full Text
View/download PDF

3. Humoral and Innate Immunological Profile of Paediatric Recipients of Pfizer-BioNTech BNT162b2 mRNA Vaccine.

Author

Jeremiah, Sundararaj Stanleyraj, Das, Priya, Venkatesan, Manu, Albinzayed, Reem, Ahmed, Aysha, Stevenson, Nigel John, Corbally, Martin, Alqahtani, Manaf, Al-Wedaie, Fatima, Farid, Eman, and Hejres, Suha

Subjects
COVID-19 vaccines, HUMORAL immunity, VIRAL antigens, NATURAL immunity, CELLULAR signal transduction
Abstract

The Pfizer-BioNTech vaccine was one of the essential tools in curtailing the COVID-19 pandemic. Unlike conventional vaccines, this newly approved mRNA vaccine is taken up by cells, which leads to the synthesis of the specific viral Spike antigen. The vaccine was initially introduced for adults, and the immunological profile of adult recipients is well-characterized. The vaccine was approved for paediatric use much later after its efficacy and safety had been confirmed in children. However, the complete picture of how the paediatric immune system in children reacts to the vaccine is not well documented. Therefore, in order to better understand the immune response in children, we analysed the humoral response, immune cell count, and interferon signalling in paediatric vaccine recipients ranging between 5 and 17 years of age. Our findings suggest that the paediatric recipients elicit a robust humoral response that is sustained for at least three months. We also found that the vaccine triggered a transient lymphocytopenia similar to that observed during viral infection. Interestingly, we also found that the vaccine may sensitise the interferon signalling pathway, priming the cells to mount a potent response when exposed to interferons during a subsequent infection. The study offers new insights into the workings of the paediatric immune system and innate immunity, thereby opening the doors for further research in this field. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach

Author

Kimura, Yayoi, Nakai, Yusuke, Shin, Jihye, Hara, Miyui, Takeda, Yuriko, Kubo, Sousuke, Jeremiah, Sundararaj Stanleyraj, Ino, Yoko, Akiyama, Tomoko, Moriyama, Kayano, Sakai, Kazuya, Saji, Ryo, Nishii, Mototsugu, Kitamura, Hideya, Murohashi, Kota, Yamamoto, Kouji, Kaneko, Takeshi, Takeuchi, Ichiro, Hagiwara, Eri, Ogura, Takashi, Hasegawa, Hideki, Tamura, Tomohiko, Yamanaka, Takeharu, and Ryo, Akihide

Published
2021
Full Text
View/download PDF

5. Development of a Monoclonal Antibody Targeting HTLV-1 Envelope gp46 Glycoprotein and Its Application to Near-Infrared Photoimmuno-Antimicrobial Strategy

Author

Hatayama, Yasuyoshi, primary, Yamaoka, Yutaro, additional, Morita, Takeshi, additional, Jeremiah, Sundararaj Stanleyraj, additional, Miyakawa, Kei, additional, Nishi, Mayuko, additional, Kimura, Yayoi, additional, Mitsunaga, Makoto, additional, Iwase, Tadayuki, additional, Kimura, Hirokazu, additional, Yamamoto, Naoki, additional, Takaori-Kondo, Akifumi, additional, Hasegawa, Hideki, additional, and Ryo, Akihide, additional

Published
2022
Full Text
View/download PDF

8. Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera

Author

Satoshi Yajima, Atsushi Goto, Jeremiah Sundararaj Stanleyraj, Takeharu Yamanaka, Tomoko Shimada, Hideaki Kato, Yutaro Yamaoka, Akihide Ryo, Kei Miyakawa, Takahiro Mihara, and Hirofumi Go

Subjects
Adult, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Biosensing Techniques, Antibodies, Viral, AcademicSubjects/SCI01180, Neutralization, Virus, Young Adult, Immune system, Application Note, Pandemic, Genetics, Humans, Molecular Biology, BNT162 Vaccine, biology, SARS-CoV-2, COVID-19, Cell Biology, General Medicine, Middle Aged, Antibodies, Neutralizing, Virology, Vaccination, Humoral immunity, Immunologic Techniques, biology.protein, Antibody
Abstract

The uncontrolled spread of the COVID-19 pandemic has led to the emergence of different SARS-CoV-2 variants across the globe. The ongoing global vaccination strategy to curtail the COVID-19 juggernaut, is threatened by the rapidly spreading Variants of Concern (VOC) and other regional mutants, which are less responsive to neutralization by infection or vaccine derived antibodies. We have previously developed the hiVNT system which detects SARS-CoV-2 neutralizing antibodies in sera in less than three hours. In this study, we modify the hiVNT for rapid qualitative screening of neutralizing antibodies (nAb) to multiple VOC of SARS-CoV-2, and assess the neutralizing efficacy of the BNT162b2 mRNA vaccine on seven epidemiologically relevant SARS-CoV-2 variants. Here we show that the BNT162b2 mRNA vaccine can activate humoral immunity against the major SARS-CoV-2 mutants that are currently in circulation. Albeit a small sample size, we observed that one dose of vaccine was sufficient to elicit a protective humoral response in previously infected people. Using a panel of seven SARS-CoV-2 variants and a single prototype virus, our modified hiVNT would be useful for large-scale community wide testing to detect protective immunity that may confer vaccine/immune passport in the ongoing COVID-19 pandemic.

Published
2021

14. Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.

Author

Miyakawa, Kei, Kato, Hideaki, Ohtake, Norihisa, Jeremiah, Sundararaj Stanleyraj, and Ryo, Akihide

Subjects
SARS-CoV-2, MEDICAL personnel, CELLULAR immunity, SARS-CoV-2 Omicron variant, COVID-19 vaccines
Abstract

The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 messenger RNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that 3 antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several postbooster breakthrough cases caused by the Omicron variant. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Persistence of robust humoral immune response in COVID-19 convalescent individuals over 12 months after infection

Author

Miyakawa, Kei, primary, Kubo, Sousuke, additional, Jeremiah, Sundararaj Stanleyraj, additional, Go, Hirofumi, additional, Yamaoka, Yutaro, additional, Ohtake, Norihisa, additional, Kato, Hideaki, additional, Ikeda, Satoshi, additional, Mihara, Takahiro, additional, Matsuba, Ikuro, additional, Sanno, Naoko, additional, Miyakawa, Masaaki, additional, Shinkai, Masaharu, additional, Miyazaki, Tomoyuki, additional, Ogura, Takashi, additional, Ito, Shuichi, additional, Kaneko, Takeshi, additional, Yamamoto, Kouji, additional, Goto, Atsushi, additional, and Ryo, Akihide, additional

Published
2021
Full Text
View/download PDF

19. Development of highly sensitive and rapid antigen detection assay for diagnosis of COVID-19 utilizing optical waveguide immunosensor

Author

Funabashi, Rikako, primary, Miyakawa, Kei, additional, Yamaoka, Yutaro, additional, Yoshimura, Seiko, additional, Yamane, Satoshi, additional, Jeremiah, Sundararaj Stanleyraj, additional, Shimizu, Kohei, additional, Ozawa, Hiroki, additional, Kawakami, Chiharu, additional, Usuku, Shuzo, additional, Tanaka, Nobuko, additional, Yamazaki, Etsuko, additional, Kimura, Hirokazu, additional, Hasegawa, Hideki, additional, and Ryo, Akihide, additional

Published
2021
Full Text
View/download PDF

20. Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors

Author

Goto, Atsushi, primary, Go, Hirofumi, additional, Miyakawa, Kei, additional, Yamaoka, Yutaro, additional, Ohtake, Norihisa, additional, Kubo, Sousuke, additional, Jeremiah, Sundararaj Stanleyraj, additional, Mihara, Takahiro, additional, Senuki, Kotaro, additional, Miyazaki, Tomoyuki, additional, Ikeda, Satoshi, additional, Ogura, Takashi, additional, Kato, Hideaki, additional, Matsuba, Ikuro, additional, Sanno, Naoko, additional, Miyakawa, Masaaki, additional, Ozaki, Haruo, additional, Kikuoka, Masakazu, additional, Ohashi, Yasuo, additional, Ryo, Akihide, additional, and Yamanaka, Takeharu, additional

Published
2021
Full Text
View/download PDF

22. Treating COVID-19: are we missing out the window of opportunity?

Author

Akihide Ryo, Manisha Gupta, Nandini Sethuraman, Rajesh Gupta, Jeremiah Sundararaj Stanleyraj, and Sohanlal Thiruvoth

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Specific time, Severe disease, Disease, Virus Replication, Antiviral Agents, Time-to-Treatment, Immunomodulation, 03 medical and health sciences, Viewpoint, 0302 clinical medicine, AcademicSubjects/MED00740, Humans, Medicine, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, Pharmacology, Natural course, Window of opportunity, SARS-CoV-2, business.industry, COVID-19, COVID-19 Drug Treatment, AcademicSubjects/MED00290, 030104 developmental biology, Infectious Diseases, Viral replication, Disease Progression, Inflammatory cascade, Cytokines, AcademicSubjects/MED00230, business, Immunosuppressive Agents
Abstract

Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a cascade of inflammatory events. Progression to severe disease is predominantly a function of the inflammatory cascade, rather than viral replication per se. This understanding can be effectively translated to changing our approach in managing the disease. The natural course of disease offers us separate windows of specific time intervals to administer either antiviral or immunomodulatory therapy. Instituting the right attack at the right time would maximize the benefit of treatment. This concept must also be factored into studies that assess the efficacy of antivirals and immunomodulatory agents against COVID-19.

Published
2020
Full Text
View/download PDF

23. SARS-CoV-2 antigen rapid diagnostic test enhanced with silver amplification technology

Author

Miyakawa, Kei, primary, Funabashi, Rikako, additional, Yamaoka, Yutaro, additional, Jeremiah, Sundararaj Stanleyraj, additional, Katada, Junichi, additional, Wada, Atsuhiko, additional, Takei, Toshiki, additional, Shimizu, Kohei, additional, Ozawa, Hiroki, additional, Kawakami, Chiharu, additional, Usuku, Shuzo, additional, Tanaka, Nobuko, additional, Yamazaki, Etsuko, additional, Shimizu, Hideaki, additional, Okabe, Nobuhiko, additional, Hasegawa, Hideki, additional, and Ryo, Akihide, additional

Published
2021
Full Text
View/download PDF

24. Development of an Automated Chemiluminescence Assay System for Quantitative Measurement of Multiple Anti-SARS-CoV-2 Antibodies

Author

Kubo, Sousuke, primary, Ohtake, Norihisa, additional, Miyakawa, Kei, additional, Jeremiah, Sundararaj Stanleyraj, additional, Yamaoka, Yutaro, additional, Murohashi, Kota, additional, Hagiwara, Eri, additional, Mihara, Takahiro, additional, Goto, Atsushi, additional, Yamazaki, Etsuko, additional, Ogura, Takashi, additional, Kaneko, Takeshi, additional, Yamanaka, Takeharu, additional, and Ryo, Akihide, additional

Published
2021
Full Text
View/download PDF

25. MAL Inhibits the Production of HIV-1 Particles by Sequestering Gag to Intracellular Endosomal Compartments.

Author

Kei Miyakawa, Mayuko Nishi, Jeremiah, Sundararaj Stanleyraj, Yuko Morikawa, and Ryo, Akihide

Subjects
HIV, FLUORESCENCE resonance energy transfer, TYPE I interferons, GAG proteins, NEGATIVE regulatory factor, ANIMAL species
Abstract

The host innate immune response is the first line of defense against human immunodeficiency virus (HIV) infection. The type I interferon (IFN) response is a robust anti-viral response that induces the transcription of several IFN-stimulated genes (ISGs). However, the effects of ISGs, particularly on the HIV-1 Gag protein, remain largely unknown. Hence, we screened ISG-encoded proteins by bioluminescence resonance energy transfer to identify the crucial host effectors that suppressed Gag function. Consequently, we identified the transmembrane protein MAL as a Gag-interacting ISG product. In fact, ectopic expression of MAL substantially inhibited the production of HIV-1 particles, leading to the translocation, accumulation, and eventual lysosomal degradation of Gag in the host endosomal compartments. Owing to the conserved N-terminal region of MAL, which specifically interacts with HIV-1 Gag, this particular antiviral function of MAL targeting Gag is also conserved among orthologs of various animal species. Notably, the antiviral activity of MAL was partially antagonized by the viral accessory protein Nef, as it interfered with the interaction between MAL and Gag. Therefore, this study reveals a previously unidentified antiviral function of MAL and its viral counteraction. It also sheds new light on therapeutic strategies against HIV-1 infection based on the intrinsic antiviral immunity of host cells. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Development of an automated chemiluminescence assay system for quantitative measurement of multiple anti-SARS-CoV-2 antibodies

Author

Kubo, Sousuke, primary, Ohtake, Norihisa, additional, Miyakawa, Kei, additional, Jeremiah, Sundararaj Stanleyraj, additional, Yamaoka, Yutaro, additional, Murohashi, Kota, additional, Hagiwara, Eri, additional, Mihara, Takahiro, additional, Goto, Atsushi, additional, Yamazaki, Etsuko, additional, Ogura, Takashi, additional, Kaneko, Takeshi, additional, Yamanaka, Takeharu, additional, and Ryo, Akihide, additional

Published
2020
Full Text
View/download PDF

27. Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles

Author

Miyakawa, Kei, primary, Jeremiah, Sundararaj Stanleyraj, additional, Ohtake, Norihisa, additional, Matsunaga, Satoko, additional, Yamaoka, Yutaro, additional, Nishi, Mayuko, additional, Morita, Takeshi, additional, Saji, Ryo, additional, Nishii, Mototsugu, additional, Kimura, Hirokazu, additional, Hasegawa, Hideki, additional, Takeuchi, Ichiro, additional, and Ryo, Akihide, additional

Published
2020
Full Text
View/download PDF

29. Identification of Serum Prognostic Biomarkers of Severe COVID-19 by Multi-Layered Quantitative Proteomic Approach

Author

Kimura, Yayoi, primary, Nakai, Yusuke, additional, Shin, Jihey, additional, Hara, Miyui, additional, Takeda, Yuriko, additional, Kubo, Sousuke, additional, Jeremiah, Sundararaj Stanleyraj, additional, Ino, Yoko, additional, Akiyama, Tomoko, additional, Moriyama, Kayano, additional, Sakai, Kazuya, additional, Saji, Ryo, additional, Nishii, Mototsugu, additional, Kitamura, Hideya, additional, Murohashi, Kota, additional, Yamamoto, Kouji, additional, Kaneko, Takeshi, additional, Takeuchi, Ichiro, additional, Hagiwara, Eri, additional, Ogura, Takashi, additional, Tamura, Tomohiko, additional, Yamanaka, Takeharu, additional, and Ryo, Akihide, additional

Published
2020
Full Text
View/download PDF

30. Highly Specific Monoclonal Antibodies Against SARS-CoV-2 Nucleocapsid Antigen for Accurate Diagnosis of COVID-19

Author

Yamaoka, Yutaro, primary, Miyakawa, Kei, additional, Jeremiah, Sundararaj Stanleyraj, additional, Okudela, Koji, additional, Nishi, Mayuko, additional, Kikuchi, Sayaka, additional, Usuku, Shuzo, additional, Kawakami, Chiharu, additional, Tanaka, Nobuko, additional, Morita, Takeshi, additional, Hayashi, Hiroyuki, additional, Mitsui, Hideaki, additional, Suzuki, Keita, additional, Aizawa, Daisuke, additional, Yoshimura, Yukihiro, additional, Miyazaki, Tomoyuki, additional, Yamazaki, Etsuko, additional, Suzuki, Tadaki, additional, Kimura, Hirokazu, additional, Hasegawa, Hideki, additional, and Ryo, Akihide, additional

Published
2020
Full Text
View/download PDF

31. Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection.

Author

Miyakawa, Kei, Kubo, Sousuke, Jeremiah, Sundararaj Stanleyraj, Go, Hirofumi, Yamaoka, Yutaro, Ohtake, Norihisa, Kato, Hideaki, Ikeda, Satoshi, Mihara, Takahiro, Matsuba, Ikuro, Sanno, Naoko, Miyakawa, Masaaki, Shinkai, Masaharu, Miyazaki, Tomoyuki, Ogura, Takashi, Ito, Shuichi, Kaneko, Takeshi, Yamamoto, Kouji, Goto, Atsushi, and Ryo, Akihide

Subjects
CORONAVIRUS diseases, COVID-19, HUMORAL immunity, COVID-19 pandemic, VIRUS diseases, ANTIBODY titer
Abstract

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits varying degrees of protective immunity conferred by neutralizing antibodies (nAbs). In this study, we report the persistence of nAb responses over 12 months after infection despite their decreasing trend noticed from 6 months. Methods The study included sera from 497 individuals who had been infected with SARS-CoV-2 between January and August 2020. Samples were collected at 6 and 12 months after onset. The titers of immunoglobulin (Ig)G to the viral nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were measured by chemiluminescence enzyme immunoassay. The nAb titer was determined using lentivirus-based pseudovirus or authentic virus. Results Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset. Although the nAb levels were likely to confer adequate protection against wild-type viral infection, the neutralization activity to recently circulating variants in some of the mild cases (~30%) was undermined, implying the susceptibility to reinfection with the variants of concerns (VOCs). Conclusions Coronavirus disease 2019 convalescent individuals have robust humoral immunity even at 12 months after infection albeit that the medical history and background of patients could affect the function and dynamics of antibody response to the VOCs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

32. Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera.

Author

Miyakawa K, Jeremiah SS, Kato H, Yamaoka Y, Go H, Yajima S, Shimada T, Mihara T, Goto A, Yamanaka T, and Ryo A

Subjects
Adult, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Biosensing Techniques, COVID-19 blood, COVID-19 immunology, Humans, Immunologic Techniques, Middle Aged, SARS-CoV-2 isolation & purification, Young Adult, Antibodies, Neutralizing blood, Antibodies, Viral blood, BNT162 Vaccine therapeutic use, COVID-19 prevention & control, SARS-CoV-2 immunology
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results